Perez, MarcoPeinado-Serrano, JavierGarcia-Heredia, Jose ManuelFelipe-Abrio, IreneTous, CristinaFerrer, IreneMartin-Broto, JavierSaez, CarmenCarnero, AmancioPerez, MarcoPeinado-Serrano, JavierGarcia-Heredia, Jose ManuelFelipe-Abrio, IreneTous, CristinaFerrer, IreneMartin-Broto, JavierSaez, CarmenCarnero, Amancio2024-10-232024-10-232016http://hdl.handle.net/10668/10392https://hdl.handle.net/20.500.12105/25210Sarcomas are malignant tumors accounting for a high percentage of cancer morbidity and mortality in children and young adults. Surgery and radiation therapy are the accepted treatments for most sarcomas; however, patients with metastatic disease are treated with systemic chemotherapy. Many tumors display marginal levels of chemoresponsiveness, and new treatment approaches are needed. MAP17 is a small non-glycosylated membrane protein overexpressed in carcinomas. The levels of MAP17 could be used as a prognostic marker to predict the response to bortezomib in hematological malignancies and in breast tumors. Therefore, we analyzed the expression of this oncogene in sarcomas and its relationship with clinico-pathological features, as well as tested whether it can be used as a new biomarker to predict the therapeutic response to bortezomib and new therapies for sarcomas. We found that the levels of MAP17 were related to clinical features and poor survival in a cohort of 69 patients with different sarcoma types, not being restricted to any special subtype of tumor. MAP17 expression is associated with poor overall survival (pengVoRhttp://creativecommons.org/licenses/by/4.0/MAP17BiomarkerBortezomibSarcomasPDXAdolescentAdultAgedAnimalsAntineoplastic AgentsArea Under CurveBiomarkers, TumorBortezomibDisease-Free SurvivalFemaleHumansKaplan-Meier EstimateMaleMembrane ProteinsMiceMiddle AgedPrognosisROC CurveSarcomaSensitivity and SpecificityXenograft Model Antitumor AssaysYoung AdultAttribution 4.0 International2756381074167033-6704610.18632/oncotarget.114751949-2553Oncotargetopen access